PATH Program

Center for Vaccine Innovation and Access

Everyone has a right to lifesaving vaccines, no matter where they live. The Center for Vaccine Innovation and Access (CVIA) accelerates the development and delivery of lifesaving vaccines for the communities facing the greatest health risks around the world.

CVIA in numbers

100s

of millions of people immunized

24+

vaccines licensed

years accelerating vaccine access

Saving lives with vaccines

CVIA has played a critical role in some of immunization’s greatest successes of the past 30 years: The world’s first malaria vaccine, which has reached more than 2 million children (and counting); elimination of meningitis A epidemics in Africa where MenAfriVac® vaccine has been introduced, with more than 360 million people immunized; protecting more than 300 million children from Japanese encephalitis, a potentially debilitating and fatal brain infection; vaccinating millions of girls in 30 countries against human papillomavirus (HPV), the leading cause of cervical cancer; and introducing the first typhoid conjugate vaccine in six countries, protecting more than 56 million children.

Tackling the toughest diseases

Our portfolio of vaccines in development and deployment includes those against the most dangerous childhood illnesses, such as pneumonia, diarrhea, and malaria. For example, beginning in 2011, we partnered to develop the world’s first malaria vaccine, and we supported implementation of the pivotal pilot introduction of the vaccine in Ghana, Kenya, and Malawi. PATH’s breadth of experience in malaria prevention and treatment, paired with our expertise in malaria vaccine implementation, uniquely equips us to support countries as they plan their rollouts of malaria vaccines.

Pioneering new vaccines

We supported the development and introduction of MenAfriVac®, a conjugate meningitis A vaccine that has been delivered to more than 360 million people across the African meningitis belt and virtually eliminated meningitis A wherever it has been used. PATH also partnered on MenFive®—the first vaccine to protect against meningitis A, C, W, Y, and X and with the potential to stop meningococcal meningitis epidemics in the meningitis belt in Africa, once and for all.

Expanding access for global impact

We transformed a Japanese encephalitis vaccine that had been available only in China into an internationally approved tool that has been delivered to more than 300 million people. With partners, we contributed to making a more affordable pneumococcal conjugate vaccine, PNEUMOSIL®, increasing protection for children against deadly pneumonia and other pneumococcal diseases like meningitis, sepsis, and otitis media.

Advancing immunization equity

We supported country-led efforts to assess the typhoid disease burden, secure support for typhoid vaccine introduction from Gavi, the Vaccine Alliance, and leveraged typhoid vaccine introduction to reach children with other essential vaccines. In Malawi, PATH partnered with the immunization and education ministries to deliver typhoid, polio, and measles vaccines in an integrated campaign.

Improving vaccine supply and affordability

We partnered with manufacturers to ensure robust supplies and cost competition of lifesaving vaccines that can be used by the World Health Organization and Gavi—and, therefore, made widely available to communities across the world. Our support on clinical development, quality systems, and regulatory strategies has resulted in more than a dozen vaccines approved (prequalified) by the World Health Organization.

Rapidly responding to outbreaks

We mobilized quickly to respond to the COVID-19 pandemic, including supporting country vaccine readiness, COVAX, and other efforts to ensure equitable access to vaccines; vaccine development and manufacturing scale-up; and vaccine clinical evaluation efforts.

Get our updates

Moving the Needle e-newsletter

Moving the Needle provides updates from CVIA on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing-country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technologies.
Immunization Matters e-newsletter

Immunization Matters provides updates from CVIA on late-stage and licensed vaccines included in our portfolio as well as our work on health economics and optimization, operations research, and support to countries.
Take on Typhoid website

The Coalition against Typhoid (CaT) and the Typhoid Vaccine Acceleration Consortium (TyVAC) have joined forces to Take on Typhoid. Together, we are working to focus attention on typhoid and the need for typhoid conjugate vaccines and water, sanitation, and hygiene interventions to reduce the burden and impact of typhoid fever.
HPVflash e-newsletter

In HPVflash, PATH provides updates on progress in the field, new literature, events, and partnerships in an effort to eliminate cervical cancer.

More about CVIA

Dr. Melanie Saville

Chief Scientific Officer, PATH
Jessica Milman

Global Head, Center for Vaccine Innovation and Access (CVIA)
Margaret Toher

Global Head, Regulatory, Center for Vaccine Innovation and Access (CVIA)
Deborah Atherly

Global Head of Policy, Access, and Introduction, Center for Vaccine Innovation and Access
Dwayne Wilson

Global Head, Quality, Center for Vaccine Innovation and Access (CVIA)
Christina Polyak

Global Head of Clinical, Center for Vaccine Innovation and Access
Simone Blayer

Global Head, Development (Chemistry, Manufacturing, and Controls), CVIA
Ashley Birkett

Global Head, Bacterial and Parasitic Diseases, Center for Vaccine Innovation and Access
John Konz

Global Head, Viral Diseases, CVIA
Gretchen MacLeod

Global Head, Integrated Portfolio and Financial Management, CVIA